Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas

被引:0
作者
Narendranath Epperla [1 ]
Timothy S Fenske [1 ]
Parameswaran N Hari [1 ]
Mehdi Hamadani [1 ]
机构
[1] Division of Hematology and Oncology,Medical College of Wisconsin
关键词
Mantle cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Autologous hematopoietic cell transplantation;
D O I
暂无
中图分类号
R733.1 [网状内皮系统肿瘤];
学科分类号
100214 ;
摘要
Lymphomas constitute the second most common indication for high dose therapy(HDT) followed by autologous hematopoietic cell transplantation(autoHCT). The intent of administering HDT in these heterogeneous disorders varies from cure(e.g., in relapsed aggressive lymphomas) to disease control(e.g., most indolent lymphomas). Regardless of the underlying histology or remission status at transplantation, disease relapse remains the number one cause of post autoHCT therapy failure and mortality. The last decade has seen a proliferation of clinical studies looking at prevention of post auto-HCT therapy failure with various maintenance strategies. The benefit of such therapies is in turn dependent on disease histology and timing of transplantation. In relapsed, chemosensitive diffuse large B-cell lymphoma(DLBCL), although post auto-HCT maintenance rituximab seems to be safe and feasible, it does not provide improved survival outcomes and is not recommended. The preliminary results with anti- programmed death-1(PD-1) antibody therapy as post auto-HCT maintenance in DLBCL is promising but requires randomized validation. Similarly in follicular lymphoma, maintenance therapies including rituximab following auto-HCT should be considered investigational and offered only on a clinical trial. Rituximab maintenance results in improved progressionfree survival but has not yet shown to improve overall survival in mantle cell lymphoma(MCL), but given the poor prognosis with post auto-HCT failure in MCL, maintenance rituximab can be considered on a caseby-case basis. Ongoing trials evaluating the efficacy of post auto-HCT maintenance with novel compounds(e.g., immunomodulators, PD-1 inhibitors, proteasome inhibitors and bruton’s tyrosine kinase inhibitors) will likely change the practice landscape in the near future for B cell non-Hodgkin lymphomas patients following HDT and auto-HCT.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 16 条
[1]  
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study[J] . Andre Goy,Rajni Sinha,Michael E. Williams,Sevgi Kalayoglu Besisik,Johannes Drach,Radhakrishnan Ramchandren,Lei Zhang,Sherri Cicero,Tommy Fu,Thomas E. Witzig.Journal of Clinical Oncology . 2013 (29)
[2]  
Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi[J] . Umberto Vitolo,Marco Ladetto,Carola Boccomini,Luca Baldini,Federico De Angelis,Alessandra Tucci,Barbara Botto,Annalisa Chiappella,Annalisa Chiarenza,Antonello Pinto,Amalia De Renzo,Francesco Zaja,Claudia Castellino,Alessia Bari,Isabel
[3]  
Tandem Autologous–Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity[J] . Sandra Cohen,Thomas Kiss,Silvy Lachance,Denis Claude Roy,Guy Sauvageau,Lambert Busque,Imran Ahmad,Jean Roy.Biology of Blood and Marrow Transplantation . 2012 (6)
[4]   Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy [J].
Li, Yi ;
Wang, Jing ;
Li, Chong ;
Ke, Xiao-Yan .
LEUKEMIA & LYMPHOMA, 2012, 53 (10) :2015-2023
[5]  
High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry[J] . Nicolas Mounier,Carmen Canals,Christian Gisselbrecht,Jan Cornelissen,Roberto Foa,Eulogio Conde,John Maertens,Michel Attal,Alessandro Rambaldi,Charles Crawley,Jian-Jian Luan,Mats Brune,Sebastian Wittnebel,Gordon Cook,G.W. van Imhoff,Michael Pfreundschuh,Anna Sureda.Biology of B
[6]  
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial[J] . Gilles Salles,John Francis Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Réda Bouabdallah,John Vincent Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppa,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin I
[7]   Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant [J].
Heutte, Natacha ;
Haioun, Corinne ;
Feugier, Pierre ;
Coiffier, Bertrand ;
Tilly, Herve ;
Ferme, Christophe ;
Gabarre, Jean ;
Morschhauser, Franck ;
Gisselbrecht, Christian ;
Mounier, Nicolas .
LEUKEMIA & LYMPHOMA, 2011, 52 (07) :1239-1248
[8]  
Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas[J] . Erica D. Warlick,Marcie Tomblyn,Qing Cao,Todd DeFor,Bruce R. Blazar,Margaret MacMillan,Michael Verneris,John Wagner,Kathryn Dusenbery,Mukta Aurora,Veronika Bachanova,Claudio Brunstein,Linda Burns,Sarah Cooley,Dan Kaufman,Navneet S. Majhail,Brian McClune,Philip McGlave,Jeffrey Miller,Betul Oran,Arne Slungaard,Gregory Ve
[9]   Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma [J].
Zhang, Wei ;
Jiao, Li ;
Zhou, Dao-Bin ;
Shen, Ti .
ONCOLOGY LETTERS, 2010, 1 (04) :733-738
[10]   Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma [J].
Tsirigotis, Panagiotis ;
Dray, Liliane ;
Resnick, Igor B. ;
Ackerstein, Aliza ;
Gesundheit, Benjamin ;
Elad, Sharon ;
Or, Reuven ;
Shapira, Michael-Yechiel .
ANNALS OF HEMATOLOGY, 2010, 89 (03) :263-272